Log in

Inventiva Stock Forecast, Price & News

+0.41 (+2.99 %)
(As of 10/20/2020 12:00 AM ET)
Today's Range
Now: $14.11
50-Day Range N/A
52-Week Range
Now: $14.11
Volume76,521 shs
Average Volume72,302 shs
Market Capitalization$538.33 million
P/E RatioN/A
Dividend YieldN/A
Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The company also develops Odiparcil, which is in Phase IIa clinical trial primarily for the treatment of mucopolysaccharidosis type VI disease; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment. It has partnership collaborations with the Institut Curie in the field of oncology; AbbVie for developing ROR? project that is used for the treatment of autoimmune diseases, as well as other projects relating to fibrosis; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.00 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:IVA
Phone33 3 80 44 75 00



Sales & Book Value

Annual SalesN/A



Market Cap$538.33 million
Next Earnings DateN/A
OptionableNot Optionable
+0.41 (+2.99 %)
(As of 10/20/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IVA News and Ratings via Email

Sign-up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Inventiva (NASDAQ:IVA) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Inventiva?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Inventiva

Who are some of Inventiva's key competitors?

Who are Inventiva's key executives?

Inventiva's management team includes the following people:
  • Mr. Frédéric Cren, Co-Founder, CEO & Chairman (Age 54)
  • Dr. Pierre Broqua, Co-Founder, Chief Scientific Officer & Deputy CEO (Age 58)
  • Mr. Jean Volatier, Chief Financial Officer (Age 56)
  • Mr. Nicolas Gueugnon, Legal Director
  • Ms. Nathalie Harroy, Head of HR

When did Inventiva IPO?

(IVA) raised $103 million in an initial public offering on Friday, July 10th 2020. The company issued 7,500,000 shares at $13.68 per share. Jefferies, Stifel and Guggenheim Securities served as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.

What is Inventiva's stock symbol?

Inventiva trades on the NASDAQ under the ticker symbol "IVA."

How do I buy shares of Inventiva?

Shares of IVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Inventiva's stock price today?

One share of IVA stock can currently be purchased for approximately $14.11.

How big of a company is Inventiva?

Inventiva has a market capitalization of $538.33 million. Inventiva employs 84 workers across the globe.

What is Inventiva's official website?

The official website for Inventiva is www.inventivapharma.com.

How can I contact Inventiva?

Inventiva's mailing address is 50 RUE DE DIJON, DAIX I0, 21121. The company can be reached via phone at 33 3 80 44 75 00 or via email at [email protected]

This page was last updated on 10/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.